The Complex I inhibitor IACS-010759 and the glutaminase inhibitor CB-839 both showed strong anti-tumor activities across cell lines and PDX models with SMARCA4/2-loss, suggesting that these clinical agents61,62 can be effective in treating SMARCA4/2-deficicent cancers. This evidence concerns the gene SMARCA4 and neoplasm.